Insurers are expecting broad adoption of wearables by their industry within the next 2 years, according to a report from Accenture.
Insurers are expecting broad adoption of wearables by their industry within the next 2 years, according to a report from Accenture.
The annual Technology Vision report highlights emerging information technology developments that will impact insurance. Accenture also outlined 5 trends that are causing insurers to stretch beyond the boundaries of traditional insurance due to technology.
“While insurers have traditionally based their underwriting and pricing processes on a limited view of certain customer variables, emerging technologies such as wearables and other connected devices can help insurers break from their traditional business models and provide outcome-based services for their customers,” John Cusano, senior managing director of Accenture’s global Insurance practice, said in a statement.
Almost two-thirds (63%) of respondents believe that wearables will be broadly adopted within 2 years, while 31% said they are already using wearables. However, the large amount of data from this technology is challenging. Most insurers are struggling to fully use the existing data. More than half (56%) said managing the data is extremely or very challenging.
The volume of data managed by organizations has grown by 50% or more over the past year, according to 44% of insurers. Those struggling with data will begin to realize that more decisions are made by software and that machines can be entrusted to make these decisions. “Intelligent enterprise” makes machines smarter and will allow insurers to get more value out of big data.
“Companies are starting to recognize the value provided by advances in language processing and speech recognition, which are making it easier for people to interact naturally with technology and machines,” Thomas Meyer, managing director of Accenture’s Insurance practice in Europe, Africa and Latin America, said. “The next-generation insurance company will benefit from human and technology collaboration, with workers leveraging new technologies such as wearables to augment their abilities and help them make better decisions.”
Overall, the 5 trends highlighted by the report include:
What We’re Reading: ChatGPT in Health Care; Menthol Ban Meeting; Health System Cyberattack Impact
November 30th 2023ChatGPT is changing health care while also raising questions about artificial intelligence's promises and limitations; 24 Biden officials met with the National Organization of Black Law Enforcement Executives to discuss the FDA’s proposal to ban menthol cigarettes; a recent hospital cyberattack shows how the vulnerability of health care systems can put patients at risk.
Read More
Emily Goldberg Shares Insights as a Genetic Counselor for Breast Cancer Risk Screening
October 30th 2023On this episode of Managed Care Cast, Emily Goldberg, MS, CGC, a genetic counselor at JScreen, breaks down how genetic screening for breast cancer works and why it is so important to increase awareness and education around these screening tools available to patients who may be at risk for cancer.
Listen
Study Validates Smartphone Analysis for Predicting Obstructive Sleep Apnea
November 29th 2023Findings show breathing sounds recorded by smartphones during sleep at home can reliably identify obstructive sleep apnea, presenting an innovative and accessible alternative to traditional in-laboratory polysomnography.
Read More
Examining Telehealth Uptake to Increase Equitable Care Access
January 26th 2023To mark the publication of The American Journal of Managed Care®’s 12th annual health IT issue, on this episode of Managed Care Cast, we speak with Christopher M. Whaley, PhD, health care economist at the RAND Corporation, who focuses on health economics issues, including the influence of the COVID-19 pandemic on health care delivery.
Listen
Researchers Identify Potential Biomarkers for SMA Motor Improvement Following Nusinersen Treatment
November 17th 2023A retrospective, exploratory analysis identifies biomarkers predictive of spinal muscular atrophy (SMA) response to nusinersen and suggests the efficacy of using machine learning algorithms to anticipate patient outcomes.
Read More
Data on Delandistrogene Moxeparvovec Can Inform Future Gene Therapies
November 17th 2023The FDA approved delandistrogene moxeparvovec-rokl (Elevidys, Sarepta Therapeutics) in June to treat Duchenne muscular dystrophy in ambulatory pediatric patients aged 4 through 5 who have a confirmed DMD gene mutation.
Read More